{"id":"NCT00658567","sponsor":"ACADIA Pharmaceuticals Inc.","briefTitle":"A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03","primaryCompletion":"2009-12","completion":"2009-12","firstPosted":"2008-04-15","resultsPosted":"2014-09-09","lastUpdate":"2017-05-19"},"enrollment":123,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease Psychosis"],"interventions":[{"type":"DRUG","name":"Pimavanserin tartrate (ACP-103)","otherNames":[]},{"type":"DRUG","name":"Pimavanserin tartrate (ACP-103)","otherNames":[]},{"type":"DRUG","name":"Pimavanserin tartrate (ACP-103)","otherNames":[]}],"arms":[{"label":"2","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"1","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.","primaryOutcome":{"measure":"Antipsychotic Efficacy","timeFrame":"Each study visit (i.e. Days 1, 8, 15, 29 and 42)","effectByArm":[{"arm":"Placebo","deltaMin":-4.4,"sd":null},{"arm":"Pimavanserin 10 mg","deltaMin":null,"sd":null},{"arm":"Pimavanserin 20 mg","deltaMin":-6.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":50,"countries":["United States","Austria","Belgium","Italy","Poland","Portugal","Serbia","Spain","Sweden"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":39},"commonTop":["Fall","Orthostatic hypotension","Somnolence","Insomnia","Hallucination"]}}